Avet-Loiseau H - Search Results

1

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. Kumar S, et al. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Lancet Oncol. 2016. PMID: 27511158 Review.

2

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.

Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, Minvielle S, Bataille R; Intergroupe Francophone du Myélome. Avet-Loiseau H, et al. Blood. 2002 Mar 15;99(6):2185-91. doi: 10.1182/blood.v99.6.2185. Blood. 2002. PMID: 11877296 Free article.

3

Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.

Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M. Spisek R, et al. Cancer Res. 2002 May 15;62(10):2861-8. Cancer Res. 2002. PMID: 12019165

4

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.

Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H; Intergroupe Francophone du Myélome. Moreau P, et al. Blood. 2002 Sep 1;100(5):1579-83. doi: 10.1182/blood-2002-03-0749. Blood. 2002. PMID: 12176874 Free article.

5

Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.

Avet-Loiseau H, Garand R, Lodé L, Harousseau JL, Bataille R; Intergroupe Francophone du Myélome. Avet-Loiseau H, et al. Blood. 2003 Feb 15;101(4):1570-1. doi: 10.1182/blood-2002-08-2436. Epub 2002 Oct 3. Blood. 2003. PMID: 12393502 Free article.

6

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S. Magrangeas F, et al. Blood. 2003 Jun 15;101(12):4998-5006. doi: 10.1182/blood-2002-11-3385. Epub 2003 Mar 6. Blood. 2003. PMID: 12623842 Free article.

7

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, Harousseau JL, Bataille R. Robillard N, et al. Blood. 2003 Aug 1;102(3):1070-1. doi: 10.1182/blood-2002-11-3333. Epub 2003 Apr 17. Blood. 2003. PMID: 12702507 Free article.

8

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.

Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, Harousseau JL, Bataille R, Minvielle S, Avet-Loiseau H. Magrangeas F, et al. Blood. 2004 May 15;103(10):3869-75. doi: 10.1182/blood-2003-07-2501. Epub 2004 Jan 8. Blood. 2004. PMID: 14715636 Free article.

9

Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.

Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. Moreau P, et al. Haematologica. 2004 May;89(5):547-51. Haematologica. 2004. PMID: 15136217

10

International staging system for multiple myeloma.

Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. Greipp PR, et al. J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809451

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

353 results

Search Page